Ranbaxy Buys Biovel For An Entry Into Vaccines and Biotherapeutics
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Lucrative opportunities in the business of vaccines has attracted one more big drug maker. India's Ranbaxy clinched a deal with Bangalore-based Biovel in an asset buyout that is expected to help it gain foothold in a market that reached $700 million in India and $21 billion in worldwide sales in 2008
You may also be interested in...
Vaccines, Biosimilars In Shadow As Sun Shines On Ranbaxy?
Sun Pharma may eliminate biosimilars and vaccines work that was being done by Ranbaxy at its two units in Hyderabad and Bangalore. The move could symbolize the thinking of Sun management – to stay away from venturing into product segments that are highly competitive or still evolving.
Vaccines, Biosimilars In Shadow As Sun Shines On Ranbaxy?
Sun Pharma may eliminate biosimilars and vaccines work that was being done by Ranbaxy at its two units in Hyderabad and Bangalore. The move could symbolize the thinking of Sun management – to stay away from venturing into product segments that are highly competitive or still evolving.
Exclusive: Rebuilding Ranbaxy – CEO Says Quality Compliance Trumps Achieving Growth Targets
Undaunted by a spate of negative news, Ranbaxy CEO Arun Sawhney says his mandate is clear: to build a strong reputation for Ranbaxy. In a discussion with PharmAsia News, Sawhney says he regrets the errors of the past that led to quality lapses, but says changes have been made to avoid similar fumbles in the future.